News

Public · Published

Morgan Stanley maintains BioMarin Pharmaceutical at Overweight, lowers price target to $119 from $122

Morgan Stanley kept its Overweight rating on BioMarin Pharmaceutical and lowered its price target to $119 from $122, a 2.5% decrease. The new target implies 107.2% upside from the November 2 close of $57.44.

Published:

Updated:

What happened

Morgan Stanley kept its Overweight rating on BioMarin Pharmaceutical and lowered its price target to $119 from $122, a 2.5% decrease. The new target implies 107.2% upside from the November 2 close of $57.44.

Confirmed

Global impact / market context

A lower target still above the share price signals the bank sees value but trimmed expectations. Overweight means Morgan Stanley expects the stock to beat the average of the stocks it covers, which can draw buyers who follow analyst ratings.

Analyst inference

Other recent notes set targets from $60 to $122 and mostly carry Hold-type ratings, so Morgan Stanley stays among the most bullish. That gap suggests opinion is split, and the wider target range can make the stock trade more on company news than on ratings.

Analyst inference

What to watch

  1. Morgan Stanley's $119 target implies 107.2% upside from the $57.44 close on November 2, so watch how far the share price moves toward or away from that level. Confirmed
  2. Watch future analyst notes, since the five most recent targets span $60 to $122; a shift in the spread could change how investors position in the stock. Analyst inference
  3. Track BioMarin's next company updates for signs that support Morgan Stanley's Overweight view; weaker results would test whether the $119 target holds. Proposed

Evidence

  • Original source link unavailable